ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00269750
Recruitment Status : Completed
First Posted : December 26, 2005
Last Update Posted : May 19, 2011
Sponsor:
Information provided by:
Alza Corporation, DE, USA

December 22, 2005
December 26, 2005
May 19, 2011
July 1996
Not Provided
Change from baseline in: the number of urge urinary incontinence episodes per week; total number of urinary incontinence episodes; total void frequency (normal and incontinent)
Same as current
Complete list of historical versions of study NCT00269750 on ClinicalTrials.gov Archive Site
Incidence of adverse events
Same as current
Not Provided
Not Provided
 
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence
The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.

Ditropan® is indicated for the treatment of urge urinary incontinence, however patients tend to discontinue the medication or decrease the dose due to anticholinergic side effects. OROS® oxybutynin, a continuous release formulation, is expected to have fewer anticholinergic side effects than Ditropan® and may provide equal or better efficacy compared to Ditropan®. This is a randomized, multi-center, double-blind, parallel group, dose-escalation study comparing the efficacy and safety of OROS® oxybutynin to Ditropan® for the treatment of urge or mixed urinary incontinence at the minimum effective dose (MED), the maximum tolerated dose (MTD), or the maximum allowable dose (MAD) permitted under this protocol. Patients in both treatment groups begin study drug treatment at an oxybutynin dose of 5 mg per day. The dose is changed in 5 mg increments at 4- to 7-day intervals, depending on the safety and efficacy of the current dose. The maximum allowable dose for Ditropan® is 20 mg per day, which is the maximum daily adult dose specified in its labeling. Because controlled delivery of oxybutynin by an OROS® dosage form could potentially reduce side effects, it is believed that the drug could possibly be tolerated at doses higher than 20 mg per day. Consequently, the maximum allowable dose for OROS® oxybutynin is 30 mg per day, administered as a single daily dose. The primary measures of effectiveness include the change from baseline in the following assessments: the number of urge urinary incontinence episodes per week, the total number of urinary incontinence episodes, and total void frequency (normal and incontinent). Safety evaluations include the incidence of adverse events, physical examination and medical history, clinical laboratory tests, urinalysis, electrocardiograms (ECGs), vital signs, and the Anticholinergic Effects Assessment (ACEA) questionnaire.

OROS® (oxybutynin chloride) 5 mg tablets, one to six tablets per day (5 mg/day to 30 mg/day) as a single morning oral dose for 11 days up to 70 days, and Ditropan (oxybutynin chloride) 5 mg tablets, one to four tablets per day orally (5 mg per day to 5 mg four times per day) for 10 daysup to 61 days.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Urge Incontinence
Drug: OROS® oxybutynin or Ditropan®
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Same as current
February 1997
Not Provided

Inclusion Criteria:

  • Patients with urge or mixed urinary incontinence, provided that stress urinary incontinence is not the predominant manifestation of mixed urinary incontinence
  • Patients who are currently taking immediate release oxybutynin (Ditropan®) hyoscyamine (Levsin®) or propantheline (Pro-banthine®), or who have taken Ditropan in the past for urge or mixed UI. (Patients who have taken Ditropan for urge or mixed urinary incontinence, but who have discontinued the medication should have discontinued due to anticholinergic effects and not due to failure of efficacy)
  • Patients who are able to differentiate incontinent episodes associated with urgency from incontinent episodes not associated with urgency when recording incontinent episodes in the diary, who have at least six urge urinary incontinence episodes per week recorded on the Run-in Diary after washout of anticholinergic medications, and who demonstrate that the number of urge incontinent episodes per week is greater than the number of incontinent episodes not associated with urgency per week
  • Patients who are in good general health prior to study participation, having normal blood pressure with or without hypertension medication
  • Agreeing that a medically acceptable and effective birth control method will be used by the patient and partner throughout the study and for one week following the end of the study

Exclusion Criteria:

  • Patients with known treatable genitourinary conditions that may cause incontinence (e.g., urinary tract infection, prostatitis, urinary tract obstruction, bladder tumor, bladder stone, prostate cancer)
  • Patients with glaucoma or untreated narrow anterior chamber angles, obstructive bowel disease or severe narrowing of the gastrointestinal tract, obstructive uropathy, or myasthenia gravis
  • Patients with known allergy or hypersensitivity to oxybutynin or clinically significant medical problems or other organ abnormality or pathology for whom, administration of oxybutynin would present undue risk
  • Male patients with a PSA > 10 ng/mL or a PSA between 4 ng/mL and 10 ng/mL who in the opinion of the investigator require further evaluation or treatment for prostate cancer, or male patients who have had prostate surgery less than nine months before study enrollment. (Prostate pathology from surgery must be benign)
  • Patients whose estimated creatinine clearance is less than 50 mL/min or a have hemoglobin level less than 10 g/dL
Sexes Eligible for Study: All
40 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00269750
CR005968
Not Provided
Not Provided
Not Provided
Not Provided
Alza Corporation, DE, USA
Not Provided
Study Director: Alza Corporation Clinical Trial Alza Corporation, DE, USA
Alza Corporation, DE, USA
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP